How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,037 results for

Pruritus in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Intrahepatic Cholestasis of Pregnancy with Severe Elevation of Bile Acids in the Setting of Acute Hepatitis C Infection Full Text available with Trip Pro

Intrahepatic Cholestasis of Pregnancy with Severe Elevation of Bile Acids in the Setting of Acute Hepatitis C Infection Intrahepatic cholestasis of pregnancy (ICP) is a complication of pregnancy resulting in elevation of serum bile acid levels. ICP is often associated with underlying liver disease, including hepatitis C. Bile acids in relationship to the acute infection of hepatitis C virus have not yet been delineated in the literature. A 26-year-old gravida 4 para 2103 with dichorionic (...) , diamniotic twin gestation and history of intravenous drug abuse developed ICP in the setting of acute hepatitis C infection. In addition to clinical symptoms of pruritus and right upper quadrant pain, she developed severe elevation in bile acids, 239 micromol/L, and transaminitis aspartate aminotransferase 1033 U/L, and alanine aminotransferase 448 U/L. She received ursodeoxycholic acid and antenatal testing was performed. Patient delivered vaginally at 33-week gestation following preterm rupture

2016 Case reports in obstetrics and gynecology

82. A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy Full Text available with Trip Pro

A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy Intrahepatic cholestasis of pregnancy (ICP) is a common liver disorder, mostly occurring in the third trimester. ICP is defined as an elevation of serum bile acids, typically accompanied by pruritus and elevated activities of liver aminotransferases. ICP is caused by impaired biliary lipid secretion, in which endogenous steroids may play a key role. Although ICP is benign for the pregnant woman

2016 PloS one

83. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. (Abstract)

Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Intrahepatic cholestasis of pregnancy (ICP) is a special complication of pregnancy characterized by skin pruritus, abnormal liver function tests and bile acids. To compare the efficacy of ursodeoxycholic acid (UDCA) and S-adenosylmethionine (SAMe) monotherapy with their combined effect on intrahepatic cholestasis of pregnancy (ICP).Singleton (...) pregnancies with ICP in five tertiary medical centers were randomly divided into three treatment groups: oral UDCA 4×250 mg daily (Group 1, n = 41), intravenous SAMe 1000 mg daily (Group 2, n = 38), and a combination of both drugs (Group 3, n = 41) until delivery. Paired t test, analysis of covariance and non-parametric test were used.All therapies significantly and equally improved pruritus. The serum levels of total bile acids (TBA), alanine aminotransferase (ALT), aspartate aminotransferase (AST

2015 European review for medical and pharmacological sciences Controlled trial quality: uncertain

84. Pregnancy and primary biliary cirrhosis: a case-control study. (Abstract)

in terms of miscarriages, voluntary interruptions of pregnancy, and term and preterm deliveries. The rates for one or more cesarean deliveries were lower for PBC patients (5.7 vs 11.7 %, p < 0.05). Pruritus during pregnancy was recorded in 15 pregnancies involving 13 PBC patients (3.0 %) and none of the controls. Perinatal and postnatal deaths and complications at childbirth were only recorded in the PBC patients, involving a total of 11 babies (2.7 %, p < 0.05). Eight pregnancies occurred after PBC (...) Pregnancy and primary biliary cirrhosis: a case-control study. A very critical feature in women's health is the identification of risk factors for pregnancy and adverse fetal outcome. Primary biliary cirrhosis is an autoimmune disease of the liver that predominantly affects older women. However, the serologic onset of this disease appears to precede clinical manifestations by many years. The goal of this case controlled study was to analyze fertility in primary biliary cirrhosis (PBC

2015 Clinical Reviews in Allergy & Immunology

85. Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG)

Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG) Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG) (PCEA-IMG) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean

2015 Clinical Trials

86. Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

immunoglobulin or alternative treatment Incidence of local/immunologic adverse events (expectant mother) [ Time Frame: Up to approximately 40 weeks, ie throughout pregnancy, and up to 6 months after delivery for final / study close out visit ] Including skin changes (such as: local erythema, local pruritus, induration, nodules) Development of anti-rHuPH20 antibodies (rHuPH20 binding and neutralizing antibodies) (expectant mother) [ Time Frame: Up to approximately 40 weeks, ie throughout pregnancy, and up (...) Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2015 Clinical Trials

87. A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy. (Abstract)

A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy. To compare the artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of acute uncomplicated falciparum malaria during pregnancy.Between January and July, 2013, a double-blind randomized trial was undertaken of symptomatic pregnant women (second/third trimester) with malaria parasitemia who attended a center in Ile-Ife, Nigeria (...) in the artesunate-amodiaquine group and 71 in the artemether-lumefantrine group completed the study. No significant differences between the artesunate-amodiaquine and artemether-lumefantrine groups were recorded for mean interval to symptomatic relief (2.2 ± 1.0 days vs 2.0 ± 0.8 days; P=0.090), day-3 parasite clearance (58/65 [89.2%] vs 66/71 [93.0%]; P=0.444), and day-28 cure rate (64/65 [98.5%] vs 67/71 [94.4%]; P=0.138). Adverse effects (body weakness and pruritus) were more common among women assigned

2015 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Controlled trial quality: predicted high

88. Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy Full Text available with Trip Pro

Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy Intrahepatic cholestasis of pregnancy (ICP) is a reversible pregnancy-specific cholestatic condition characterized by pruritus, elevated liver enzymes, and increased serum bile acids. It commences usually in the late second or third trimester, and quickly resolves after delivery. The incidence is higher in South American and Scandinavian countries (9.2%-15.6% and 1.5%, respectively) than in Europe (0.1%-0.2

2015 World journal of gastroenterology : WJG

89. Serum Autotaxin Levels in Cholestasis of Pregnancy

Training and Research Hospital Information provided by (Responsible Party): Hakan Erenel, Sisli Hamidiye Etfal Training and Research Hospital Study Details Study Description Go to Brief Summary: Intrahepatic cholestasis of pregnancy is the most common liver disease in pregnancy. It is is a pregnancy-specific liver disorder with onset mainly in the third trimester of pregnancy. ICP is characterized by pruritus, elevated serum fasting bile salts and transaminases and an increased risk of adverse fetal (...) Serum Autotaxin Levels in Cholestasis of Pregnancy Serum Autotaxin Levels in Cholestasis of Pregnancy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Serum Autotaxin Levels in Cholestasis of Pregnancy

2015 Clinical Trials

90. Efficacy and Safety Study of PAC-14028 Cream in Dermal Pruritus

Eczema or dry skin on the study drug application site Women of childbearing potential should have a negative urine pregnancy test at screening and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period. Voluntarily signed written informed consent forms for study participation. Exclusion Criteria: Pruritus due to other medical (liver disease, renal failure, etc.), psychotic (...) participation. History of physical treatment for pruritus, including phototherapy, within 1 month prior to study participation. Patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period. Renal function impairment with creatinine level Hepatic function impairment with aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) Pregnant and lactating women Participation in another clinical study

2014 Clinical Trials

91. Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02143973 Recruitment Status : Completed First Posted : May 21, 2014 Last Update Posted : August 28, 2018 Sponsor: Trevi

2014 Clinical Trials

92. Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

or anticipated to be receiving nocturnal dialysis or home hemodialysis treatment during the study. Subject has pruritus that is believed to be caused by a condition unrelated to end-stage renal disease Has had a history of substance abuse within 6 months prior to completing Screening Subject has a known drug allergy to opioids Subject is a pregnant or lactating female. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact (...) Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2014 Clinical Trials

93. Dose-dependent attenuation of intravenous nalbuphine on epidural morphine-induced pruritus and analgesia after cesarean delivery. Full Text available with Trip Pro

Dose-dependent attenuation of intravenous nalbuphine on epidural morphine-induced pruritus and analgesia after cesarean delivery. Epidural morphine in patient-controlled analgesia regimens controls postoperative pain well but easily induces pruritus and other epidural morphine-related side effects. With 90 pregnant American Society of Anesthesiologists physical status II females scheduled for elective cesarean delivery, the present study was designed to evaluate the efficacy and safety profile (...) of patient-controlled antipruritus (PCP) use of intravenous nalbuphine-based regimens for attenuation of postoperative pruritus and related side effects in combination with epidural morphine patient-controlled analgesia with regard to the quality of postoperative pain management. Patients were randomly assigned to two nalbuphine groups (5 μg/kg/hour, Group N5 or 10 μg/kg/hour, Group N10) and bolus dose of 1.6 μg/kg for PCP or the control (normal saline) group. Comparable visual analog scale scores

2014 The Kaohsiung journal of medical sciences Controlled trial quality: uncertain

94. Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

to severe pruritus Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures Exclusion Criteria: Surgical disruption of the enterohepatic circulation Liver transplant History or presence of other concomitant liver disease Females who are pregnant or lactating Known HIV infection Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation

2014 Clinical Trials

95. Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus

for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: History of pruritus of >8 weeks duration. Severity score of pruritus ≥5 as defined by VAS Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream) Negative pregnancy test result for all participating women of childbearing age; Exclusion Criteria: Known allergy to Calmmax cream Any acute illness (...) Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy

2014 Clinical Trials

96. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. Full Text available with Trip Pro

Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. To test whether ursodeoxycholic acid reduces pruritus in women with intrahepatic cholestasis of pregnancy, whether early term delivery does not increase the incidence of caesarean section, and the feasibility of recruiting women with intrahepatic cholestasis of pregnancy to trials of these interventions.First (...) phase of a semifactorial randomised controlled trial.Nine consultant led maternity units, United Kingdom.125 women with intrahepatic cholestasis of pregnancy (pruritus and raised levels of serum bile acids) or pruritus and raised alanine transaminase levels (>100 IU/L) recruited after 24 weeks' gestation and followed until delivery. 56 women were randomised to ursodeoxycholic acid, 55 to placebo, 30 to early term delivery, and 32 to expectant management.Ursodeoxycholic acid 500 mg twice daily

2012 BMJ Controlled trial quality: predicted high

97. Pruritus and Systemic Disease (Diagnosis)

, cholestasis of pregnancy, and end-stage liver disease of any cause. Drug-induced cholestasis may be caused by chlorpropamide, tolbutamide, phenothiazines, erythromycin, anabolic steroids, and oral contraceptives. Hematologic pruritus may be seen in association with the following conditions: Iron deficiency Polycythemia rubra vera Hypereosinophilic syndrome Essential thrombocythemia Myelodysplastic syndrome Endocrine pruritus may be seen in association with the following disorders: Hyperthyroidism (...) of leukemia. Sex The sex of the patient does not seem to be associated with pruritus in systemic diseases. Certain causes of cholestasis are more common in women than in men. These include primary biliary cirrhosis (90% of patients are women) and cholestasis of pregnancy. Primary biliary cirrhosis is thought to be an autoimmune disease that causes destruction of the small and medium bile ducts, leading to cholestasis. It most often occurs in women in the fourth or fifth decade of life, but it can occur

2014 eMedicine.com

98. Pruritus and Systemic Disease (Overview)

, cholestasis of pregnancy, and end-stage liver disease of any cause. Drug-induced cholestasis may be caused by chlorpropamide, tolbutamide, phenothiazines, erythromycin, anabolic steroids, and oral contraceptives. Hematologic pruritus may be seen in association with the following conditions: Iron deficiency Polycythemia rubra vera Hypereosinophilic syndrome Essential thrombocythemia Myelodysplastic syndrome Endocrine pruritus may be seen in association with the following disorders: Hyperthyroidism (...) of leukemia. Sex The sex of the patient does not seem to be associated with pruritus in systemic diseases. Certain causes of cholestasis are more common in women than in men. These include primary biliary cirrhosis (90% of patients are women) and cholestasis of pregnancy. Primary biliary cirrhosis is thought to be an autoimmune disease that causes destruction of the small and medium bile ducts, leading to cholestasis. It most often occurs in women in the fourth or fifth decade of life, but it can occur

2014 eMedicine.com

99. Pruritus and Systemic Disease (Treatment)

and is effective but may only be available in intravenous form. [ ] To prevent opioid withdrawal syndrome, low starting doses should be used. These drugs should not be used in patients in need of palliative opioid treatment. Butorphanol, which antagonizes the mu receptor but agonizes the kappa receptor, has been shown to be effective in suppressing cholestatic pruritus. [ ] Ursodeoxycholic acid and S-adenosyl-L-methionine have both been reported to decrease pruritus in women with cholestasis of pregnancy (...) , Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology . 1997 Oct. 113(4):1264-9. . Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol . 1999 Sep. 41(3 Pt 1):431-4. . Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy

2014 eMedicine.com

100. Pruritus and Systemic Disease (Follow-up)

and is effective but may only be available in intravenous form. [ ] To prevent opioid withdrawal syndrome, low starting doses should be used. These drugs should not be used in patients in need of palliative opioid treatment. Butorphanol, which antagonizes the mu receptor but agonizes the kappa receptor, has been shown to be effective in suppressing cholestatic pruritus. [ ] Ursodeoxycholic acid and S-adenosyl-L-methionine have both been reported to decrease pruritus in women with cholestasis of pregnancy (...) , Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology . 1997 Oct. 113(4):1264-9. . Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol . 1999 Sep. 41(3 Pt 1):431-4. . Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>